{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=59",
    "query": {
      "condition": "Carcinoma, Bronchogenic",
      "page": 59
    },
    "page_size": 10
  },
  "pagination": {
    "page": 59,
    "page_size": 10,
    "total_count": 3591,
    "total_pages": 360,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=60&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Bronchogenic&page=58&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T20:44:57.929Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04748419",
      "title": "Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer",
        "Carcinoma, Non-Small Cell Lung"
      ],
      "interventions": [
        {
          "name": "consolidative hypofractionated radiation therapy (hfRT)",
          "type": "RADIATION"
        },
        {
          "name": "Durvalumab 50 MG/ML",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG"
      ],
      "sponsor": "University of Nebraska",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2021-07-15",
      "completion_date": "2025-09-26",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-10-25T20:44:57.929Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04748419"
    },
    {
      "nct_id": "NCT03576131",
      "title": "GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer",
        "Non-small Cell Lung Cancer",
        "Triple Negative Breast Cancer",
        "Renal Cell Carcinoma",
        "Gastric Cancer",
        "Pancreatic Cancer",
        "Urothelial Cancer"
      ],
      "interventions": [
        {
          "name": "GEN1029 (HexaBody®-DR5/DR5)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2018-04-30",
      "completion_date": "2021-10-12",
      "has_results": true,
      "last_update_posted_date": "2023-08-01",
      "last_synced_at": "2026-10-25T20:44:57.929Z",
      "location_count": 2,
      "location_summary": "New Haven, Connecticut • Houston, Texas",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03576131"
    },
    {
      "nct_id": "NCT00034957",
      "title": "Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung",
        "Lung Neoplasms"
      ],
      "interventions": [
        {
          "name": "Investigational drug",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": "2002-10",
      "has_results": false,
      "last_update_posted_date": "2012-02-16",
      "last_synced_at": "2026-10-25T20:44:57.929Z",
      "location_count": 12,
      "location_summary": "Berkeley, California • Greenbrae, California • Los Angeles, California + 9 more",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Rancho Mirage",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00034957"
    },
    {
      "nct_id": "NCT00085501",
      "title": "S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer"
      ],
      "interventions": [
        {
          "name": "cetuximab",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 242,
      "start_date": "2004-07",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2012-11-01",
      "last_synced_at": "2026-10-25T20:44:57.929Z",
      "location_count": 163,
      "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • Berkeley, California + 113 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Burlingame",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085501"
    },
    {
      "nct_id": "NCT00516100",
      "title": "Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aptium Oncology Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2006-01",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2010-01-15",
      "last_synced_at": "2026-10-25T20:44:57.929Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Palm Springs, California • San Francisco, California + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Elizabeth",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00516100"
    },
    {
      "nct_id": "NCT03515629",
      "title": "REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "REGN2810/ipi",
          "type": "DRUG"
        },
        {
          "name": "REGN2810/chemo/ipi",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2018-07-02",
      "completion_date": "2021-07-29",
      "has_results": true,
      "last_update_posted_date": "2022-11-16",
      "last_synced_at": "2026-10-25T20:44:57.929Z",
      "location_count": 1,
      "location_summary": "St. Petersburg, Florida",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03515629"
    },
    {
      "nct_id": "NCT02595931",
      "title": "M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Colorectal Carcinoma",
        "Metastatic Lung Small Cell Carcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Pancreatic Carcinoma",
        "Refractory Colorectal Carcinoma",
        "Refractory Lung Small Cell Carcinoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Pancreatic Carcinoma",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage III Lung Cancer AJCC v8",
        "Stage III Pancreatic Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Lung Cancer AJCC v8",
        "Stage IV Pancreatic Cancer AJCC v8",
        "Unresectable Colorectal Carcinoma",
        "Unresectable Lung Small Cell Carcinoma",
        "Unresectable Malignant Solid Neoplasm",
        "Unresectable Pancreatic Carcinoma"
      ],
      "interventions": [
        {
          "name": "Berzosertib",
          "type": "DRUG"
        },
        {
          "name": "Biopsy Specimen",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2016-07-22",
      "completion_date": "2027-03-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-25T20:44:57.929Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Palo Alto, California • Pasadena, California + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02595931"
    },
    {
      "nct_id": "NCT01814553",
      "title": "ADAM-Afatinib Diarrhea Assessment and Management",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "afatinib",
          "type": "DRUG"
        },
        {
          "name": "loperamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2013-04",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2016-10-31",
      "last_synced_at": "2026-10-25T20:44:57.929Z",
      "location_count": 12,
      "location_summary": "Santa Rosa, California • Orlando, Florida • Port Saint Lucie, Florida + 7 more",
      "locations": [
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Skokie",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01814553"
    },
    {
      "nct_id": "NCT03101839",
      "title": "Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Advanced Solid Tumours"
      ],
      "interventions": [
        {
          "name": "AZD4785",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 28,
      "start_date": "2017-05-15",
      "completion_date": "2019-01-08",
      "has_results": false,
      "last_update_posted_date": "2019-10-04",
      "last_synced_at": "2026-10-25T20:44:57.929Z",
      "location_count": 3,
      "location_summary": "Sarasota, Florida • Boston, Massachusetts • Nashville, Tennessee",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03101839"
    },
    {
      "nct_id": "NCT03455556",
      "title": "Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Mesothelin Positive",
        "Stage III Non-Small Cell Lung Cancer AJCC v7",
        "Stage IIIA Non-Small Cell Lung Cancer AJCC v7",
        "Stage IIIB Non-Small Cell Lung Cancer AJCC v7",
        "Stage IV Non-Small Cell Lung Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Anetumab Ravtansine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2018-08-10",
      "completion_date": "2020-01-07",
      "has_results": true,
      "last_update_posted_date": "2023-01-06",
      "last_synced_at": "2026-10-25T20:44:57.929Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03455556"
    }
  ]
}